Literature DB >> 7695317

Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.

A A van Zwet1, J C Thijs, B de Graaf.   

Abstract

In 4 of 17 Helicobacter pylori strains obtained from antral biopsy samples, the registered primary resistance (MIC, > 32 microgram/ml) appeared to be nonstable after prolonged microaerophilic incubation. In all resistant strains tested, susceptibility could be obtained when culture under normal microaerophilic conditions was preceded by a period of anaerobic incubation. Both of these findings may explain the observed discrepancy between the results of in vitro susceptibility tests and the eradication obtained in vivo.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7695317      PMCID： PMC162519          DOI： 10.1128/AAC.39.1.250

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action.

Authors:  D I Edwards
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

Review 3.  Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance.

Authors:  D I Edwards
Journal:  J Antimicrob Chemother       Date:  1993-02       Impact factor: 5.790

4.  In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori.

Authors:  A A van Zwet; J C Thijs; W Schievink-de Vries; J Schiphuis; J A Snijder
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole.

Authors:  A M Hirschl; M M Hirschl; M L Rotter
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

6.  Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker.

Authors:  Y Wang; K P Roos; D E Taylor
Journal:  J Gen Microbiol       Date:  1993-10

7.  The E test for antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; A Ljungh
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

8.  Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori.

Authors:  S L Lacey; S F Moss; G W Taylor
Journal:  J Antimicrob Chemother       Date:  1993-09       Impact factor: 5.790

9.  Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance.

Authors:  A J DeCross; B J Marshall; R W McCallum; S R Hoffman; L J Barrett; R L Guerrant
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

10.  Proposed mechanism for metronidazole resistance in Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; A Ljungh
Journal:  J Antimicrob Chemother       Date:  1992-02       Impact factor: 5.790
View more
  10 in total

Review 1.  Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

2.  Helicobacter pylori in children: acquisition of antimicrobial resistance after an initial course of treatment.

Authors:  N Kalach; P H Benhamou; C Dupont; J Raymond; M Bergeret; F Gottrand; M O Husson
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

3.  Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.

Authors:  M Sörberg; H Hanberger; M Nilsson; A Björkman; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Helicobacter pylori and radical therapy for peptic ulcer.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1995-11       Impact factor: 2.401

5.  Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.

Authors:  Marygorret Obonyo; Li Zhang; Soracha Thamphiwatana; Dissaya Pornpattananangkul; Victoria Fu; Liangfang Zhang
Journal:  Mol Pharm       Date:  2012-08-06       Impact factor: 4.939

6.  Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned?

Authors:  Doron Boltin; Haim Ben-Zvi; Tsachi Tsadok Perets; Zvi Kamenetsky; Zmira Samra; Ram Dickman; Yaron Niv
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

Review 7.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

8.  Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

Review 9.  Helicobacter pylori.

Authors:  B E Dunn; H Cohen; M J Blaser
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

10.  Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance.

Authors:  M Dehesa; J Larisch; M Dibildox; M Di Silvio; L H Lopez; E Ramirez-Barba; J Torres
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.